WEST LAFAYETTE, Ind., May 16, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, are scheduled to participate in the following investor conferences:
UBS Global Healthcare Conference
New York City
May 23-25, 2022
Group presentation: Tuesday, May 24, 2022 at 7:45 a.m. ET
Craig-Hallum Institutional Investor Conference
June 1, 2022
One-on-one and small group meetings only
Jefferies Healthcare Conference
New York City
June 8-10, 2022
Group presentation: Friday, June 10, 2022 at 12:15 p.m. ET
A webcast of the UBS and Jefferies group presentations will be accessible on the Company’s website at: https://www.inotivco.com/investors/investor-information/.
Inotiv management will be participating in one-on-one meetings during all events.
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotivco.com/.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
Bioanalytical Systems, Inc., dba Inotiv
Beth A. Taylor, Chief Financial Officer
The Equity Group Inc.
Kalle Ahl, CFA